M&A / Deals Obesity biotech Kailera’s record-breaking IPO PharmaphorumWhen Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge - and that expectation has now been fulfilled.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaphorum When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced SettingNext: Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
